arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Maze Therapeutics, Inc.

MAZE

$28.50 ▲ +0.71 (+2.55%) at close

9 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Maze Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5B

Dividend Yield —

Revenue Growth —

Op. Margin -132.8%

ROIC -5.5% ↗

FCF / Share $-0.73

Trailing P/E —

Price / Book 4.2x

FCF Yield —

Debt / Equity 0.11

info Valuation on last close. End-of-day price, Aug 6, 2026.

9-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$20.00M

— —

Net Income Profit after all expenses

$-24.21M

↑ +26.2% —

Operating Margin Operating profit as % of sales

-132.8%

↓ -257.0% —

FCF / Share Free cash flow per share

$-0.73

↑ +30.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗
EPS Growth YoY (%)	60.9% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	71.0% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	93.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	91.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	26.2% Excellent ↑ Excellent Improving Year-over-year change in net income	-16.9% Weak ↓ Weak Declining Year-over-year change in net income	-0.9% Weak → Weak Stable Year-over-year change in net income	-0.9% Weak Weak Year-over-year change in net income	-0.9% Weak Weak Year-over-year change in net income	—	—	—	—
FCF Growth YoY (%)	30.2% Excellent Excellent Year-over-year change in free cash flow	—	94.4% Excellent Excellent Year-over-year change in free cash flow	N/M	89.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗
Operating Margin (%) (%)	-132.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-985%)	—	—	—	—	—	—	84.6% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+464%)	—
Effective Tax Rate (%) (%)	—	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	0.9% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	-121.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1109%)	—	—	—	—	—	—	-19.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-264%)	—
FCF Margin (%) (%)	-196.0% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	87.8% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	1.62x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	-4.46x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution Caution Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗
Return on Invested Capital (%)	-5.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-10.7% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-8.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	9.5% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-6.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-9.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-7.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-12.0% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-10.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-12.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—
Return on Common Equity (%) (%)	-7.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-147%)	-9.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-165%)	-8.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-158%)	-12.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-183%)	-11.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-175%)	9.5% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-37%)	—	—	—

⚖️ Is the balance sheet risky? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗
Debt to Equity (x)	0.11x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-81%)	—	—	—	—	—	—	—	—
Net Debt (USD)	$-159.93M	$-189.25M	$-316.77M	$-264.54M	$-294.37M	$-196.81M	$-149.61M	$-175.06M	$-30.02M
Debt / EBITDA (x)	-1.49x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗
Revenue per Share (USD)	$0.37	—	—	$0.00	—	—	$1.03	$69.06	—
Basic EPS, GAAP (USD)	$-0.45	$-0.60	$-0.66	$-0.77	$-1.15	$-2.07	$-10.25	$5.92	$-13.91
Free Cash Flow per Share (USD)	$-0.73	—	$-0.54	$-0.70	$-1.04	—	$-9.65	$60.64	$-10.15
Book Value per Share (USD)	$6.87	$7.19	$7.89	$5.98	$6.67	$-127.18	—	—	—
Tangible Book Value per Share (USD)	$6.87	$7.19	$7.89	$5.98	$6.67	$-127.18	—	—	—
Basic Weighted Avg Shares (shares)	53.90M	—	45.78M	43.80M	28.63M	—	2.42M	2.39M	2.34M

🏦 How resilient is the balance sheet? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗
Working Capital (USD)	$358.54M	$327.16M	$369.19M	$251.25M	$281.09M	$181.00M	—	—	—
LT Debt (USD)	$38.83M	—	—	—	—	—	—	—	—
Total Equity (USD)	$341.70M	$354.97M	$379.44M	$262.24M	$292.07M	$-311.18M	—	—	—

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗
Sales/Revenue/Turnover (USD)	$20.00M	—	—	$0.00	—	$0.00	$2.50M	$165.00M	—
Depreciation Expense (USD)	$444.00K	$499.00K	$571.00K	$649.00K	$684.00K	$705.00K	$788.00K	$854.00K	$950.00K
Net Income, GAAP (USD)	$-24.21M	$-34.57M	$-32.79M	$-32.79M	$-32.79M	$-29.58M	$-32.49M	$-32.49M	$-32.49M
Operating Cash Flow (USD)	$-39.11M	$-27.73M	$-24.64M	$-30.05M	$-29.52M	$-22.45M	$-23.20M	$145.05M	$-23.44M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 2 years · 9 quarters

Maze Therapeutics, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare MAZE with peers